Fortress Biotech (FBIO) Stock Statistics & Valuation Metrics

Fortress Biotech has a market cap or net worth of $69.92M. The enterprise value is $43.77M.

Fortress Biotech has 29,754,753 shares outstanding. The number of shares has decreased by -2.65% in one year.

Fortress Biotech’s return on equity (ROE) is -2.02 and return on invested capital (ROIC) is -145.47%.

The current PE Ratio of Fortress Biotech is ―. Fortress Biotech’s PEG ratio is ―.

In the last 12 months, Fortress Biotech had revenue of 57.67M and earned -46.00M in profits. Earnings per share was -2.69.

In the last 12 months, operating cash flow was -80.09M and capital expenditures 0.00, giving a free cash flow of -80.09M billion.

Fortress Biotech pays an annual dividend of ―, resulting in a dividend yield of ―

Fortress Biotech upcoming earnings date is Nov 17, 2025, TBA (Confirmed).

Fortress Biotech as a current ratio of 1.27, with Debt / Equity ratio of 333.64%

In the past 12 months, Fortress Biotech has paid 312.00K in taxes.

Fortress Biotech EV to EBITDA ratio is -0.58, with an EV/FCF ratio of -0.64.

Fortress Biotech has $74.39M in cash and marketable securities with $69.22M in debt, giving a net cash position of -$5.17M billion.

Gross margin is 67.37%, with operating margin of -191.38%, and net profit margin of -79.75%.

The average price target for Fortress Biotech is $14.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy